There are currently no authorised vaccinations for Respiratory Syncytial Virus (RSV) anywhere in the world. However, competition to develop the first one for this life-threatening disease is escalating as Phase 3 data that GSK disclosed will prepare it for regulatory submissions that the company plans to make later this year. In order to obtain regulatory clearance for its RSV vaccine candidate, GSK’s other competitor, Pfizer, is also on schedule. In the clinical trial, GSK’s vaccine showed 94.1% efficacy. Clinical studies are still being conducted to assess both the yearly GSK shot revaccination and longer-term immunity across several seasons. The signs and symptoms of RSV can be similar to those of the common cold, but in individuals with weakened immune systems, such as young children and the elderly, the virus can be fatal.
Read More from MedCityNews
